Mankind Pharma acquires Bharat Serums and Vaccines for $1.6bn
Mankind Pharma has announced a definitive agreement for the acquisition of a 100% stake in Bharat Serums and Vaccines (BSV)…
25 Jul 2024
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Ipsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement potentially worth $461m with Day One Biopharmaceuticals for its paediatric glioma therapy Ojemda (tovorafenib). Ipsen…
24 Jul 2024
AstraZeneca grows oncology portfolio with Pinetree’s EGFR degrader
AstraZeneca has signed a licensing agreement with Pinetree Therapeutics for a preclinical epidermal growth factor receptor (EGFR) degrader candidate, potentially worth more than $545m. AstraZeneca will pay $45m upfront for…
23 Jul 2024
Agilent agrees to acquire BIOVECTRA for $925m
Agilent Technologies has announced a definitive agreement for the acquisition of Canadian contract development and manufacturing organisation (CDMO) BIOVECTRA in a $925 deal. BIOVECTRA focuses on manufacturing biologics, highly potent…
23 Jul 2024
Grünenthal gains Valinor Pharma and constipation drug Movantik
Grünenthal has announced the acquisition of US-based Valinor Pharma, along with its opioid-induced constipation (OIC) therapy Movantik, in a $250m deal which includes complete royalty obligations. The transaction will be…
19 Jul 2024
Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial
Exscientia has taken full ownership of an oral cyclin-dependent kinase 7 (CDK7) inhibitor after buying out its development partner GT Apeiron Therapeutics’ shares of the programme. The UK-based company paid…
16 Jul 2024
SOTIO partners with Biocytogen to expand ADC oncology pipeline
SOTIO Biotech has signed a research and licensing agreement with China-based Biocytogen to develop multiple bispecific antibody-drug conjugate (ADC) candidates for treating solid tumours. As part of the agreement, Biocytogen…